Entheon Biomedical Corp.

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-30 am EDT			5-day change	1st Jan Change
0.165 ^CAD	+3.12%		-17.50%	+65.00%

Apr. 29	Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
Apr. 18	Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding	CI

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding

April 17, 2024

On April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug.

19, 2024.

Latest news about Entheon Biomedical Corp.

Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 29	CI
Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding	Apr. 17	CI
Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding	Apr. 10	CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 25	CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-25	CI
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer	23-07-31	CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-26	CI
Heading Health Inc. announced that it has received $4.5 million in funding from a group of investors	23-06-28	CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-28	CI
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin	23-04-28	CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt	23-03-22	CI
Entheon Biomedical Corp. Announces Resignation of Ruth Chun as Director	23-03-02	CI
Entheon Biomedical Corp. Announces CFO Changes	23-01-05	CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-31	CI
Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101	22-10-05	CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-26	CI
Entheon Biomedical Corp. cancelled the transaction announced on April 5, 2022	22-06-06	CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-29	CI
Entheon Biomedical Corp. announced that it expects to receive CAD 3 million in funding	22-04-04	CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2021	22-03-30	CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform	22-03-29	MT
Entheon Biomedical Corp. Announces Enrollment in Phase 1 Study of DMT	22-03-15	CI
Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose	22-02-24	CI
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study	22-02-16	CI

Chart Entheon Biomedical Corp.

Duration

Period

More charts

Company Profile

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENTHEON BIOMEDICAL CORP.	+65.00%	1.06M
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research